Biodel Files for Offering

Biodel Inc. (Nasdaq: BIOD) has filed for a secondary public offering of $3.81 million common shares. Sellers include Great Point Partners, OrbiMed Advisors and Vivo Ventures. Each firm would retain shares in Biodel following the sale. Biodel is a Danbury, Conn.-based drug improvement company focused on endocrine disorders like diabetes and osteoporosis. It went public last May.